FEEDBACK

In his interview with THE SCIENTIST (June 1, 1987, p. 14), William R. Graham, the current White House science adviser, commenting on relations between the administration and the scientific community regarding SDI, said, “I think we need to have a more reasoned discourse on the subject and draw more on the industrial sector as well as the academic sector. I think that will help moderate some of the positions being taken, as we get more information injected into the process.” We woul

Written byDaniel Fisher
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

In his interview with THE SCIENTIST (June 1, 1987, p. 14), William R. Graham, the current White House science adviser, commenting on relations between the administration and the scientific community regarding SDI, said, “I think we need to have a more reasoned discourse on the subject and draw more on the industrial sector as well as the academic sector. I think that will help moderate some of the positions being taken, as we get more information injected into the process.”

We would like to point out to Graham and to your readers that an open letter to Congress expressing “serious concerns about Sf1” has been signed by 2,100 scientists and engineers from 81 industrial and government laboratories.

The open letter reads in part: “We believe that realization of this dream [rendering nuclear weapons impotent and obsolete] is not feasible in the foreseeable future... We urge the Congress to limit the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies